NKTR

MKT CAP:$2B

Nektar Therapeutics

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$56.62+$13.20 (+30.40%)

Jun 8, 2026

52W High $100.3552W Low $8.51

Company Details

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlyin...

CEO

—

IPO Date

May 3, 1994

Website

www.nektar.com

Key Metrics TTM

Revenue

$56M

-36.2% YoY

Net Income

-$158M

EPS (Diluted)

Free Cash Flow

-$204M

Revenue / Share

$2.25

Gross Margin

99.4%

Operating Margin

-224.9%

Net Margin

-284.2%

FCF Margin

-366.6%

P/S

39.4x

P/E

Earnings Reports

Q2 2026

Aug 6, 2026

PENDING

Q1 2026

May 8, 2026

$11M+3.8%

FY 2025

Mar 13, 2026

$55M-43.9%

Q4 2025

Mar 13, 2026

$22M-25.3%

Q3 2025

Nov 7, 2025

$12M-51.1%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee